Cochlear Implant Market Revenue Would Increase 3.7x By 2032

Healthcare

Fact MR Analysis of Cochlear Implant provides compelling insights into the factors propelling sales prospects in key segments. It provides an executive-level blueprint of key market players’ strategies and analyses their impact on overall growth projections

According to Fact MR’s recent market research, Cochlear Implant sales will increase at propelled CAGR by 2031, as investment towards expansion of healthcare infrastructure continues rising. The goal of the survey is uncover growth opportunities, key trends, growth drivers, and challenges. It also provides recommendations to assist businesses in preparing for unforeseen challenges.

Request For Sample

Market Segments Covered in Cochlear Implant Market Analysis

  • By Fitting Type

    • Unilateral Implants
    • Bilateral Implants
  • By End-Use

    • Adult
    • Pediatric
  • By Region

    • North America
    • Latin America
    • Europe
    • APAC
    • MEA

Competitive Analysis

Players in the market are constantly developing innovative solutions as well as extending their product offerings. To help healthcare organisations combat the Covid-19 pandemic, and preserve competitive advantage in the market, the companies are focused on their alliances, technology collaborations, and product launch strategies.

Some of the recent developments of key Cochlear Implant providers are as follows:

  • In April 2022Cochlear Ltd.‘s Cochlear Nucleus Implants were approved by the FDA for the treatment of unilateral hearing loss (ULH) or single-sided deafness (SDD).
  • In January 2022, TODOC, a South Korean company that specializes in neural prosthetic devices and neuromodulation systems, has announced that its artificial cochlear device ‘SULLIVAN’ will be unveiled at the “CES 2022” in Las Vegas.
  • In June 2021, Oticon Medical received premarket approval (PMA) from the United States Food and Drug Administration (U.S. FDA) for its Neuro System (cochlear implant system) to treat patients aged 18 years or more with bilateral severe-to-profound sensorineural hearing loss who receive limited benefit from appropriately fitted hearing aids.
  • In December 2020, after receiving FDA approval to expand its product offerings, Sonova launched two new sound processors, Sky CI Marvel and Nada CI Marvel.

Similarly, recent developments related to companies Cochlear Implant services have been tracked by the team at Fact.MR, which are available in the full report.

Leave a Reply

Related Posts